<DOC>
	<DOCNO>NCT03085238</DOCNO>
	<brief_summary>M-Trap implantable medical device design capture disseminate tumor cell ( DTCs ) . It intend use advanced-stage ovarian cancer patient . The study objective ass safety performance M-Trap device .</brief_summary>
	<brief_title>Metastatic Tumor Cell Trap Device Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Is female ≥18 year old . 2 . Presents diagnosis Stage IIIC ovarian cancer . 3 . Presents highgrade serous carcinoma . 4 . Has one following : 1 . Visible residual tumor ≤1 cm primary tumor debulking surgery . 2 . Three cycle neoadjuvant chemotherapy complete resection interval tumor debulking surgery . 3 . Three cycle neoadjuvant chemotherapy visible residual tumor ≤1 cm interval tumor debulking surgery . 5 . ECOG performance status 0 1 . 6 . Is willing comply require followup study visit . 7 . Is willing able provide write informed consent . 1 . Has life expectancy &lt; 3 month . 2 . Is pregnant , confirm blood test prior study procedure , plan become pregnant study , lactate . 3 . Will receive intraperitoneal chemotherapy . 4 . Has undergone prior treatment abdominal and/or pelvic radiotherapy . 5 . Has significant active concurrent medical illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 6 . Presence central nervous system cerebral metastasis . 7 . Recurrent ovarian cancer . 8 . Complete resection residual tumor primary tumor debulking surgery . 9 . Suboptimal resection &gt; 1 cm residual tumor primary interval tumor debulking surgery . 10 . Is simultaneously enrol another investigational study . 11 . Has history cancer within 5 year insitu uterine cervix cancer nonmelanoma skin cancer . 12 . Has know hypersensitivity carboplatin paclitaxel . 13 . Is concurrently use antineoplastic agent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>